GLI3 comprises several functional domains: repressor domain (RD, aa106-aa263), zinc-finger DNA binding domain (ZNF, aa462-aa645), proteolytic cleavage site (PC, aa703-aa740), CREB binding protein domain (CBP, 827-1131), transactivation domain 2 (TA2, aa1044-aa1322) and transactivation domain 1 (TA1, aa1376- aa1580), [
7,
8]. GLI3 has a dual function as a transcriptional activator and a repressor of the SHH pathway — the full-length GLI3 acts as an activator after phosphorylation and nuclear translocation, while its C-terminally truncated form by protease clearage acts as a repressor [
3,
9,
10]. A proper balance between the GLI3 activator and the repressor, organized by hedgehog signaling, elicits proper evolvement of the various organs during development [
11‐
13]. Pathogenic variants in different domains of the gene underlie several congenital diseases including GCPS (MIM ID#175700), PHS (MIM ID #146510), preaxial polydactyly type IV (MIM ID #174700), and postaxial polydactyly types A1 and B (MIM ID #174200), Acrocallosal Syndrome (MIM ID #200990), trigonocephaly with craniosynostosis and polydactyly, and some types of oral-facial-digital syndromes [
14]. Typical GCPS involves polysyndactyly of hands and feet, and craniofacial abnormality. Different genetic alterations (from chromosomal deletion to a single nucleic acid mutation in the ZNF domain that reduces the functioning of both the activator and repressor forms of the GLI3 protein) cause GCPS [
15]. PHS, on the other hand, shows a lethal condition involving hypothalamic dysfunction, skeletal limb defects, craniofacial and urogenital malformation attributed to pathogenic variants of GLI3 gene, typically within or around the PC domain of the GLI3 protein, resulting in a relative reduction in the functioning of the GLI3 repressor form [
16]. Since a delicate balance between the functioning activator and repressor is essential for proper development [
2,
17,
18], the simple location of the pathogenic variants in GLI3 site does not always clearly correlate with the clinical manifestations [
19]. Also, some pathogenic variants cause overlapping phenotypes of GCPS and PHS [
19]. Therefore, the concept of GLI3 morphopathies has been postulated to designate these mutually overlapped syndromes [
5].
In the current study, we demonstrated a case of GLI3 morphopathy attributed to a novel likely pathogenic variant by missense mutation at the PC domain (p.P719S) of GLI3 (variant was judged as likely pathogenic based on the criteria by American College of Medical Genetics and Genomics and the Association for Molecular Pathology, ACMG standards and guidelines [
20]). Indeed, in silico predictions of the newly found variant (p.P719S) of GLI3 gene via the predictive algorithms (PolyPhen-2,
http://genetics.bwh.harvard.edu/pph2) shows that this mutation is predicted to be “PROBABLY DAMAGING” with a score of 0.963 (sensitivity: 0.78; specificity: 0.95).Interestingly, besides gastrointestinal malformations, agenesis of both the gallbladder and the pancreas was observed. During the early stages of organogenesis, the liver, the gallbladder and the biliary duct system arise as buds in the endodermal epithelium at the distal end of the foregut. A small caudal portion of the liver bud then expands to form the gallbladder [
21]. The pancreas develops also from the endodermal epithelium of the duodenal diverticula, initially as two separate dorsal and ventral pancreatic buds, which then fuse when the duodenum rotates [
22]. SHH signaling is expressed in the ventral foregut endoderm from which the liver derives, and its expression disappears at the onset of liver bud formation [
21,
22]. Such sophisticated spatial and sequential SHH signaling is essential for proper organ development from these endodermal buds. Because we have not done comprehensive genomics study, possibility of coincidental additional pathogenic variants in Pdx1, Ptf1a, Gata4 and Gata6, known to be associated with agenesis of pancreas [
23], cannot be excluded in this case. Although it remains unclear why agenesis of the gallbladder and the pancreas is uncommon in GLI3 morphopathy, a slight difference in the gradient or the balance between activator and repressor induced by a slight difference of protein tertiary structure may contribute to the apparent phenotypic difference in GLI morphopathy.